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Throughout the body, the epithelial Na+ channel (ENaC) plays a criti-
cal role in salt and liquid homeostasis. 
In cystic fibrosis airways, for instance, 
improper regulation of ENaC results in 
hyperabsorption of sodium that causes 
dehydration of airway surface liquid. 
This dysregulation then contributes to 
mucus stasis and chronic lung infections. 
ENaC is known to undergo proteolytic 
cleavage, which is required for its ability 
to conduct Na+ ions. We have previously 
shown that the short, palate lung and 
nasal epithelial clone (SPLUNC1) binds 
to and inhibits ENaC in both airway 
epithelia and in Xenopus laevis oocytes. 
In this study, we found that SPLUNC1 
was more potent at inhibiting ENaC 
than either SPLUNC2 or long PLUNC1 
(LPLUNC1), two other PLUNC family 
proteins that are also expressed in airway 
epithelia. Furthermore, we were able to 
shed light on the potential mechanism 
of SPLUNC1’s inhibition of ENaC. 
While SPLUNC1 did not inhibit proteo-
lytic activity of trypsin, it significantly 
reduced ENaC currents by reducing the 
number of ENaCs in the plasma mem-
brane. A better understanding of ENaC’s 
regulation by endogenous inhibitors may 
aid in the development of novel therapies 
designed to inhibit hyperactive ENaC in 
cystic fibrosis epithelia.
Introduction
ENaC is the rate-limiting step for Na+ 
absorption in the airways.1-3 The impor-
tance of appropriately regulated ENaC 
activity is illustrated by the pathogenesis 
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that results when this  channel fails to 
 function correctly. For example, hyperab-
sorption of Na+ through ENaC has been 
proposed as an initiating event in cystic 
fibrosis (CF) lung disease.4,5 This likely 
occurs because Na+ hyperabsorption con-
tributes to mucus dehydration and mucus 
stasis, which prevents clearance of inhaled 
pathogens.4-6 Furthermore, Na+ hyperab-
sorption, volume depletion, and inflam-
mation have recently been demonstrated 
in transgenic mice overexpressing ENaC, 
thus directly linking ENaC and the ini-
tiation of chronic lung disease.7 In con-
trast, as ENaC is downregulated in the 
monogenic disorder, pseudohypoaldoste-
ronism, it leads to an abundance of  airway 
surface liquid and mucus transport rates 
that are significantly increased above 
 normal levels.8
ENaC is regulated by intracellular 
second messengers including cAMP and 
PIP
2
.9,10 However, extracellular serine pro-
teases also regulate ENaC.1,11 Rossier and 
colleagues initially identified a membrane-
bound serine protease that acts as a chan-
nel activating protease (CAP) that they 
termed CAP1.12 The activation of ENaC by 
CAP1 can be mimicked by external addi-
tion of trypsin and the effects are not addi-
tive, indicating that CAP1 and trypsin act 
via the same pathway. Additional CAPs, 
termed CAP2 (TMPRSS4) and CAP3 
(matriptase) have also been identified as 
being able to activate ENaC by increasing 
its open probability (Po), without any sig-
nificant change in channel density or con-
ductance.13,14 The effect of these CAPs can 
be blocked by the Kuitz-type serine prote-
ase inhibitor aprotinin,12,14 which prevents 
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SPLUNC2 expression increased by 2.4- 
and 1.5-fold at 6 and 24 h post-SMM addi-
tion, respectively.26 To test whether these 
other PLUNC family members could also 
affect ENaC activity, we expressed α, β, γ 
ENaC in Xenopus oocytes and measured 
their subsequent amiloride-sensitive cur-
rent under control conditions and follow-
ing coinjection with either SPLUNC1, 
SPLUNC2 or LPLUNC1. ENaC currents 
were reduced by ~70% when SPLUNC1 
was coinjected into the oocytes (Fig. 1). 
In contrast, co-injection of SPLUNC2, 
which has 24% amino acid homology to 
SPLUNC1, or LPLUNC1, which has two 
domains rather than the single domain 
of the SPLUNC subgroup, and has 30% 
amino acid homology to SPLUNC1, had 
no significant effect on ENaC activity 
(Fig. 1).
To understand how SPLUNC1 
 regulated ENaC, we examined whether 
SPLUNC1 could alter the proteolytic 
activity of trypsin. We have previously 
observed significant inhibition of ENaC 
by SPLUNC1 at 50 ng/ml, which is 
equivalent to 1.79 nM. At this concentra-
tion, SPLUNC1 did not alter the ability of 
trypsin to cleave a serine protease-specific 
fluorogenic substrate, while the trypsin-
specific inhibitor aprotinin, also admin-
istered at 1.79 nM, abolished proteolytic 
cleavage (Fig. 2). Thus, we conclude that 
the regulation of ENaC by SPLUNC1 
does not result from direct protease 
inhibition.
We have previously shown that 
SPLUNC1 can inhibit both basal and 
trypsin-stimulated ENaC currents.25 The 
most straightforward explanation for 
this phenomenon is that that the num-
ber of ENaCs in the plasma membrane 
had been reduced by SPLUNC1. To 
test this hypothesis directly, we surface 
-biotinylated oocytes and then probed 
for αENaC surface expression levels in 
the presence and absence of SPLUNC1. 
SPLUNC1 indeed decreased the total 
amount of αENaC in the plasma mem-
brane, as compared to controls that did 
not express SPLUNC1 (Fig. 3A). In con-
trast SPLUNC1 did not affect whole-cell 
αENaC protein levels (Fig. 3B).
In order to confirm SPLUNC1’s ability 
to reduce ENaC levels in the plasma mem-
brane, we used the sulfhydryl-reactive 
and prevents its proteolytic cleavage by 
serine proteases including trypsin, CAP1 
and CAP2.25 Since little is known about 
SPLUNC1-ENaC interactions, we fur-
ther explored their relationship and here 
we report that among the other PLUNC 
family members expressed in HBECs, 
SPLUNC1 alone significantly inhib-
its ENaC. We also demonstrate that 
SPLUNC1 exerts its effects on ENaC by 
lowering the number of ENaCs available 
for cleavage at the plasma membrane.
Results
We have previously demonstrated that 
SPLUNC1 is secreted into the media of 
SPLUNC1-injected oocytes where it binds 
to the extracellular loops of the α, β, γ 
ENaC subunits, resulting in ENaC inhibi-
tion.25 Data-mining of existing gene array 
data revealed that other PLUNC fam-
ily members are expressed in our HBEC 
system, suggesting that other PLUNCs 
may be secreted into the airway surface 
liquid and could also regulate ENaC.26 
Specifically, LPLUNC1 was endogenously 
expressed in HBECs and SPLUNC2 was 
not expressed under basal conditions. 
After exposing HBECs to supernatant of 
mucopurulent material (SMM), which 
is derived from CF airway secretions 
and acts as a powerful pro-inflamma-
tory agent,27 LPLUNC1 and SPLUNC1 
expression were not altered. However, 
the cleavage of ENaC and the subsequent 
conduction of Na+ in both primary human 
bronchial epithelial  cultures (HBECs) and 
Xenopus oocytes.15-17
The palate lung and nasal  epithelial 
clone (PLUNC) family can be subdi-
vided into short (SPLUNC) and long 
(LPLUNC) proteins that contain either 
one or two subdomains respectively.18 
In this classification, the original pro-
tein called PLUNC is now SPLUNC1.19 
SPLUNC1 is expressed in submucosal 
glands of normal individuals,20 and expres-
sion is increased in cystic fibrosis (CF) 
lungs, especially in the surface epithelia 
of the conducting airways.21 SPLUNC1 
is an abundant protein secreted into the 
airway surface liquid of HBECs.22 Early 
 characterization of SPLUNC1’s sequence 
identity uncovered some structural homol-
ogy with anti-microbial proteins and 
incited theories that SPLUNC1 would 
similarly function in a direct innate host 
defense capacity.23 To date, however, this 
theory remains uncertain. Investigators 
have reported minimal anti-microbial 
function of SPLUNC1,24 and no binding 
to lipopolysaccaride, as might be expected 
from its strong homology to lipopolysac-
caride binding proteins.22 In contrast to 
its putative anti-microbial actions, we 
identified SPLUNC1 as a potent inhibi-
tor of ENaC in both Xenopus oocytes 
and in human airway epithelia.25 We also 
found that SPLUNC1 binds to ENaC 
Figure 1. SPLunC1, but not other PLunC family members, inhibits enaC activity. Current is dis-
played relative to amiloride-sensitive current from α, β, γ enaC-expressing oocytes (ctrl, white bar; 
n = 18). Oocytes co-expressing SPLunC1 showed a ~70% reduction in enaC current (p < 0.0001; 
n = 22). However, those co-expressing SPLunC2 (n = 22) or oocytes co-expressing LPLunC1 had 
no significant enaC current reduction (n = 17). * denotes p < 0.05 different to control oocytes 
expressing α, β, γ enaC.
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have demonstrated this  mechanism  exclu-
sively in oocytes (Fig. 3), we have previ-
ously shown that SPLUNC1 decreases 
the ENaC/trypsin-sensitive potential 
difference in HBECs, suggesting that 
SPLUNC1 inhibits ENaC in a similar 
mechanism in airway epithelia.25
ENaC is trafficked to and from the 
plasma membrane in a highly regu-
lated fashion29-31 and we speculate that 
SPLUNC1’s binding to ENaC may 
directly induce a conformational change 
in ENaC that triggers its internaliza-
tion. Alternatively, SPLUNC1 has several 
putative adaptor protein 2 (AP2) bind-
ing domains and adaptor proteins have 
been identified as components in the 
ENaC internalization pathway.32,33 Thus, 
a complex containing SPLUNC1, ENaC 
and AP2 may facilitate ENaC’s internal-
ization. Finally, SPLUNC1 may also act 
as a pore blocker, in a fashion analogous 
to amiloride, though with less reversible 
binding.34 Such behavior could lead to 
a reduction in both basal and protease-
activated ENaC currents and cannot be 
formerly excluded although this mode of 
inhibition alone is inconsistent with the 
observed decrease in N (Fig. 3).
In summary, we have shown that 
SPLUNC1, but not other PLUNC family 
interacting with ENaC and not by direct 
inhibition of extracellular proteases.
The mechanism of SPLUNC1’s 
 interaction with ENaC is currently 
unknown. However, SPLUNC1 inhibits 
both basal- and trypsin-activated ENaC 
currents,25 which may provide additional 
insight into its mechanism of action. The 
macroscopic ENaC current (I) is a prod-
uct of the single channel conductance (g) 
multiplied by both the open probability 
(P
o
) and the number of channels in the 
plasma membrane (N). Proteolytically-
induced changes in I have been mainly 
attributed to altered P
o
, which can be 
induced by trypsin exposure and rapidly 
reversed by aprotinin.12 In contrast, we 
found that acute trypsin exposure failed 
to fully reverse the effects of SPLUNC1,25 
suggesting that SPLUNC1’s actions are 
not exclusively limited to changes in P
o
. 
Our present data indicate that SPLUNC1 
reduces the number of ENaC subunits at 
the plasma membrane, without affecting 
overall cellular ENaC levels (Fig. 3A and 
B). These data are consistent with the 
effects of SPLUNC1 on ENaC currents 
(Fig. 3C). For example, such a reduction 
in N would serve to lower basal ENaC cur-
rents in addition to preventing MTSET 
from further activating ENaC. While we 
reagent [2-(trimethylammonium)
ethyl methanethiosulfonate, bromide] 
(MTSET), which locks ENaC contain-
ing a S518C mutation in the β subunit 
(βS518C) into the fully open position and 
thus yields an electrical approximation 
of the number of active channels in the 
plasma membrane.28 With this system, a 
reduction in α,  βS518C, γ-ENaC current in 
the presence of MTSET would indicate 
fewer ENaCs in the plasma membrane, 
which we observed in oocytes coinjected 
with SPLUNC1 (Fig. 3C). Moreover, the 
fold-stimulation of α, βS518C, γ-ENaC cur-
rents by MTSET was 5.32 ± 0.45 while 
groups co-expressing SPLUNC1 had a 
8.05 ± 0.48 fold increase. This indicates 
that ENaC resident on the cell surface in 
SPLUNC1 expressing oocytes reside in a 
low open probability state. Together with 
the enhanced fold-stimulation by tryp-
sin,25 these results suggest that SPLUNC1 
limits proteolysis of ENaC by reducing 
ENaC surface density (Fig. 3C).
Discussion
We have previously reported that 
SPLUNC1 inhibits ENaC, likely via 
direct, extracellular binding to all three 
ENaC subunits.25 Following on from these 
findings, we were curious to know whether 
the other PLUNC family members that 
are expressed in our HBEC system would 
produce similar inhibitory effects. While 
SPLUNC1 inhibits ENaC by ∼70%, 
SPLUNC2 and LPLUNC1 do not signifi-
cantly inhibit ENaC (Fig. 1). These data 
are in keeping with our previous observa-
tions that the knockdown of SPLUNC1 to 
greater than 90% by shRNA upregulated 
ENaC activity in HBECs and led to air-
way surface liquid volume hyperabsorp-
tion, despite expression of other PLUNC 
family members in these epithelia.25 
Interestingly, SPLUNC1 is able to reduce 
ENaC currents by 70% when applied at 
50 ng/ml (1.79 nM) either in the Xenopus 
oocytes or in HBECs lacking endogenous 
SPLUNC1,25 while this concentration 
of SPLUNC1 produces negligible direct 
effects on the proteolytic activity of tryp-
sin, suggesting that SPLUNC1 does not 
act as a protease inhibitor (Fig. 2). Thus, 
based on this and our previous data,25 we 
conclude that SPLUNC1 acts by directly 
Figure 2. SPLunC1 is not a protease inhibitor. the trypsin-specific fluorogenic trypsin substrate 
Boc-Gln-Ala-Arg-mCA, emits fluorescence upon cleavage. trypsin (1 u/ml, ■); trypsin and apro-
tinin (1.79 nm, ●); trypsin and SPLunC1 (1.79 nm, ▲). Boc-Gln-Ala-Arg-mCA alone (○). All n = 4.
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Media collected from HEK293 cells not 
expressing SPLUNC1 was purified using 
the same ethanol/acetone precipitation 
method and was used as a control.
Oocyte studies. Xenopus laevis oocytes 
were harvested and injected as described.25 
In brief, defolliculated healthy stage V–
VI oocytes were injected with 0.3 ng 
of cRNA of each ENaC subunit or co-
injected with 1 ng of SPLUNC1 cRNA. 
Injected oocytes were kept in modified 












 and 15 HEPES, adjusted to 
pH 7.35 with Tris). Oocytes were studied 
24 h after injection using the two-elec-
trode voltage clamp technique as previ-
ously described.17,25 Oocytes were clamped 
at a holding potential of -60 mV. The 
change in amiloride-sensitive whole cell 
current as an indicator of ENaC activity 
was determined by subtracting the cor-
responding current value measured in 
the presence of 10 µM amiloride from 
that measured before the application of 
amiloride. For each group, whole cell cur-
rents were presented as relative currents 
to control oocytes injected with ENaC 
and water. Thus, these control groups are 
assigned a relative current of 1, as units 
reported are nA/nA.
Western blotting. Protein was 
 harvested from Xenopus oocytes, resolved 
using SDS-PAGE and transferred to 
PVDF. The membrane was then probed 
using an anti-V5 monoclonal antibodies 
(Invitrogen) as previously described.25
Surface labeling. Xenopus oocytes 
were injected with V5-CT(C-terminus)-
tagged α, untagged-β, γ rat ENaC sub-
units (0.3 ng each) ± V5/6His-tagged 
SPLUNC1 (1 ng). After 24 h, oocytes 
(70 per experimental condition) were pre-
chilled on ice for 30 minutes and labeled 
with 0.7 mg/ml sulfo-NHS-biotin in 










), 16.3 HEPES titrated to pH 
8.0 with NaOH, while tumbling gently 
for 20 min at 4°C. Oocytes were washed 
twice with chilled MBS-Ca++ buffer and 
incubated in MBS-Ca++ buffer with 100 
mM glycine for 10 min at 4°C to quench 
free biotin. Oocytes were washed again 
three times with chilled MBS-Ca2+ buf-
fer. Proteins were extracted as previously 
Figure 3. SPLunC1 decreases the number of αenaC subunits in the plasma membrane. (A) 
Surface biotinylation of αenaC shows that plasma membrane enaC is decreased following 
coexpression with SPLunC1 in Xenopus oocytes. Samples were analyzed by western blot using an 
anti-V5 (for V5/6His-tagged SPLunC1 and for V5-Ct-tagged αenaC) monoclonal antibody Lane 1, 
control; Lane 2, αβγenaC; Lane 3, αβγenaC & SPLunC1. total lysate per lane was equivalent to 3–4 
oocytes and was run on a 10% Gel. (B) Whole cell western blot of oocytes probing for αenaC (top), 
SPLunC1 and actin (bottom) shows that total enaC levels are not decreased by SPLunC1. total 
lysate per lane was equivalent to 3–4 oocytes and was run on a 12% Gel. (C) Addition of mtSet 
to enaC containing the βS518C mutant increases enaC Po to 1.0 when coexpressed in oocytes yet 
the overall current is still reduced by SPLunC1 expression. Open bars, control. Closed bars, mtSet 
addition, n = 6 for each group. * denotes p < 0.05 different ± mtSet; † denotes p < 0.05 different ± 
SPLunC1.
members, induces a potent inhibition of 
macroscopic ENaC current. While the 
mechanism of SPLUNC1’s inhibition of 
ENaC is not fully understood, we have 
found that SPLUNC1 is capable of reduc-
ing the number of ENaC multimers at 
the plasma membrane. This is the first 
report of an endogenously secreted pro-
tein that can facilitate removal of ENaC 
from the plasma membrane, and identifies 
a potential new avenue for therapeutic 
r egulation of Na+ absorption.
Methods
SPLUNC1 protein purification. 
V5/6His-tagged SPLUNC1 was stably 
expressed in HEK293 cells and purified 
from their media as previously described 
using ethanol and acetone precipitation.21 
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Trypsin MCA assay. The trypsin 
 fluorogenic substrate assay was performed 
using 96 well black plates (Corning 
Costar). Boc-Gln-Ala-Arg-MCA (100 
µM; Peptides International) was added to 
each well in 100 µl Ringer total volume. 
Aprotinin (Sigma-Aldrich) or SPLUNC1 
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Statistical analyses. All data are 
 presented as the mean ± SE for n experi-
ments. Each oocyte study was repeated 
on three separate occasions. Differences 
between means were tested for statisti-
cal significance using paired or unpaired 
t tests or their non-parametric equiva-
lent as appropriate to the experiment. 
Differences between groups were judged 
using ANOVA. From such comparisons, 
differences yielding p ≤ 0.05 were judged 
to be significant.
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